Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the liraglutide market grown in recent years?

In the past few years, there has been a significant increase in the size of the liraglutide market. Predictions indicate that it will expand from $6.38 billion in 2024 to $6.95 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.0%. Factors catalyzing this growth during the historic period include an uptick in the diagnosis of type 2 diabetes, ballooning obesity rates, widespread clinical trials, heightened awareness of the implications of diabetes, and the emergence of innovative drug delivery systems.

How is the liraglutide market size expected to evolve during the forecast period?

In the coming years, the liraglutide market is set to witness robust expansion, escalating to $9.66 billion by 2029, with an 8.6% compound annual growth rate (CAGR). Factors contributing to this positive projection during the forecast period range from enhanced insurance coverage and reimbursement methodologies, improvements in the healthcare infrastructure, increased knowledge and educational strategies, the rise in the older demographics, and a heightened occurrence of diabetes. Future trends within this period are expected to encompass the incorporation of artificial intelligence and machine learning, the growing demand for wearable technology, the integration of continuous glucose monitoring, progress in biotechnology, and the creation of digital health platforms.

Get your liraglutide market report here!

https://www.thebusinessresearchcompany.com/report/liraglutide-global-market-report

Which key drivers are propelling the liraglutide market’s growth?

The growth of the liraglutide market is anticipated to be fueled by the rising diabetic population. Diabetes, a long-term disorder wherein the body struggles to regulate blood sugar levels due to insufficient insulin production or ineffective insulin utilization, is seeing an upward trend. This increase in diabetes is attributed to factors such as inactive lifestyles, unhealthy food habits, and a global surge in obesity. Liraglutide, a diabetes medication, aids by replicating the effect of the GLP-1 hormone, increasing insulin release, reducing blood sugar, and supporting weight loss, thus aiding to control type 2 diabetes. For example, as per a report from the UK Government, a domestic information website, in March 2023, the percentage of individuals with type 1 diabetes in England that received all the eight-care processes from GP practices participating in the NDA rose to 43.8%, an increase from 35.2% the previous year. Therefore, the burgeoning diabetic population is contributing to the expansion of the liraglutide market.

What are the market segments in the liraglutide industry?

The liraglutide market covered in this report is segmented –

1) By Brands: Victoza, Saxenda

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Stores, Online Pharmacies

3) By Type Of Application: Diabetes Treatment, Weight Management

4) By End-Users: Hospitals And Clinics, Homecare Settings

Subsegments:

1) By Victoza: Type 2 Diabetes Treatment Or Weight Management

2) By Saxenda: Weight Loss Treatment Or Obesity Management

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18659&type=smp

Which leading companies are shaping the growth of the liraglutide market?

Major companies operating in the liraglutide market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Hanmi Pharmaceutical Co. Ltd., Intarcia Therapeutics Inc., Adocia SA

Which trends are expected to transform the liraglutide market?

Leading enterprises in the liraglutide market are focusing on creating innovative products like the generic GLP-1, with the intent to broaden the available treatment alternatives and cater to the market’s need for cost-effective options. Generic GLP-1 translates to variants of GLP-1 receptor agonists, which are developed post the patent protection expiry of the original branded medicines, providing affordable alternatives to manage conditions such as type 2 diabetes and obesity. To give an example, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical firm, launched the first generic GLP-1, akin to Victoza, in the U.S market in June 2024 to satisfy the growing need for these treatments. Liraglutide injections are recommended to improve blood sugar control in adults and children over the age of 10 who have type 2 diabetes and to mitigate the incidence of heart-related events in adults suffering from type 2 diabetes and pre-existing cardiovascular diseases.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18659

Which geographic areas are influencing the growth of the liraglutide market?

North America was the largest region in the liraglutide market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Biomarkers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Anti-Aging Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anti-aging-global-market-report

Antidiarrheals Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antidiarrheals-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: